Study of TG-1801 in Subjects With B-Cell Lymphoma
NCT03804996
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
B-Cell Lymphoma
Interventions
DRUG:
TG-1801
BIOLOGICAL:
Ublituximab
Sponsor
TG Therapeutics, Inc.